Experimental Drug/treatment for Esophycas and stomach cancer

sghajar
sghajar Member Posts: 16
edited March 2014 in Esophageal Cancer #1
My dad has esophycas and stomach cancer. We had 4 sessions of chemo prior to drastic surgery. They have removed 3/4 of esophycas and 1/4 of stomach + 22 lynph nodes. A month after the surgery and on 1st day of chemo, we found out that the cancer is back on his neck, lungs, and some chest lynph nodes. We are truly devasted and fighting against time. Currently the treatment is 4-6 cycle of Chemo + radiation. Is there any experimental drugs or treatment that can help us? God Bless.

Comments

  • Unknown
    Unknown
    #2
    This comment has been removed by the Moderator
  • dwhite0002
    dwhite0002 Member Posts: 126 Member
    #3
    drug suggestion
    I had success with Erbitux (spelling???). You might have your doctor look into it...it specifically attacks epithelial (skin)tissue.

    Best wishes and God-speed,

    David,
    Hillsboro, OH
  • sghajar
    sghajar Member Posts: 16
    #4
    unknown said:

    This comment has been removed by the Moderator

    Thank You
    Thank you so much for your kind email, and related information.
    It was a great help to me.
    Currently they are not giving my dad Cisplatin. He is only receiving CAPECITABINE and 5-FLUOROURACIL. The nurse called me today and I asked her if they should give dad Cisplatin with CAPECITABINE and 5-FLUOROURACIL. She said they want to see if the chemo works prior to adding Cisplatin.

    I have been researching the solution and cure for this cancer even if it is experimental:
    _________________________________________________________________________________________________
    http://clinicaltrials.gov/ct2/show/NCT00635596?term=micromet+bite&rank=1

    MT110 is a bispecific (anti-EpCAM x anti-CD3) T-cell engager (BiTE) designed to link EpCAM (epithelial cell adhesion molecule) expressing cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against EpCAM+ cells. In vitro and ex-vivo data indicate that EpCAM+ tumor cell lines are sensitive to MT110 mediated cytotoxicity. Furthermore, data from in-vivo experiments with both MT110 and a mouse surrogate molecule (muS110) have confirmed the activity of these molecules in inhibiting the formation of metastases but also against established tumors. In vitro and ex-vivo data suggest that a prolonged presence of the drug in target tissues may result in significant T-cell recruitment, activation and expansion to/in target tissues, potentially resulting in substantial anti-tumor activity in man.

    Company working on this research is Micromet
    _________________________________________________________________________________________________

    http://www.atcs.jp/pdf/2008_14_1/3.pdf
    Recent Advances in Esophageal Cancer Gene Therapy

    This article talks about gene P53 as cause of many EC.
    _________________________________________________________________________________________________

    Thanks for your information again.
    Best Regards,
    Shideh Ghajar

Discussion Boards